Conatus Pharmaceuticals (CNAT) Tops Q3 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Conatus Pharmaceuticals (CNAT) Tops Q3 EPS by 7c

Conatus Pharmaceuticals Reports Third Quarter 2015 Financial Results and Program Updates

November 4, 2015 4:07 PM EST

SAN DIEGO, Nov. 4, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq: CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and nine months ended September 30, 2015, and provided updates on its clinical development programs.

Financial Results

The net loss for the third quarter of 2015 was $6.1 million compared with $6.4 million for the third quarter of 2014. The net loss for the first nine months of 2015 was $18.1 million compared with $17.0 million for the first nine months of 2014.

Research and... More